Cencora, Inc. (NYSE: COR) has announced the pricing of several senior notes in an underwritten registered public offering. The notes include $500 million aggregate principal amount of 3.950% senior notes due February 13, 2029, $500 million aggregate principal amount of 4.250% senior notes due November 15, 2030, $500 million aggregate principal amount of 4.600% senior notes due February 13, 2033, $1.0 billion aggregate principal amount of 4.900% senior notes due February 13, 2036, and $500 million aggregate principal amount of 5.650% senior notes due February 13, 2056.
The offering is expected to close on February 13, 2026, subject to customary closing conditions. Cencora intends to use the net proceeds from the offering to repay amounts outstanding under its 364-day term credit agreement, dated as of January 12, 2026, which was used to fund a portion of its acquisition of OneOncology, and for general corporate purposes.
The joint book-running managers for the offering are Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC.
Cencora is a leading global pharmaceutical solutions organization with more than $300 billion in annual revenue.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As a result of these announcements, the company's shares have moved -0.14% on the market, and are now trading at a price of $354.85. If you want to know more, read the company's complete 8-K report here.
